Halozyme Therapeutics (HALO) Gross Margin (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Gross Margin of 78.97% for Q1 2026, down 276.0% year-over-year from 44.87% in Q1 2025, and down 4.36% quarter-over-quarter from 82.56% in Q4 2025.
Halozyme Therapeutics (HALO) Gross Margin (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Gross Margin for 17 consecutive years, with 78.97% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin fell 276.0% year-over-year to 78.97%; the TTM figure through Mar 2026 stood at 82.79% (down 66.0% YoY), while the FY2025 annual figure was 83.62%, down 68.0% from the prior year.
- Gross Margin fell to 78.97% in Q1 2026 per HALO's latest filing, from 82.56% in the prior quarter.
- Across five years, Gross Margin topped out at 86.42% in Q1 2022 and bottomed at 74.62% in Q3 2023.
- Historically, Gross Margin has averaged 80.97% across 5 years, with a median of 81.73% in 2025.
- Annual changes were most pronounced in 2023 — Gross Margin sank 811 bps — and 2024, when it soared 862 bps.
- Halozyme Therapeutics' Gross Margin stood at 76.79% in 2022, then rose by 1 bps to 77.27% in 2023, then advanced by 11 bps to 85.89% in 2024, then slipped by 4 bps to 82.56% in 2025, then decreased by 4 bps to 78.97% in 2026.
- Business Quant data shows HALO's Gross Margin at 78.97% in Q1 2026, 82.56% in Q4 2025, and 84.41% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 83.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83.54% |
| Mar 31, 2026 | 78.97% |
| Dec 31, 2025 | 82.56% |
| Sep 30, 2025 | 84.41% |
| Jun 30, 2025 | 85.77% |
| Mar 31, 2025 | 81.73% |
| Dec 31, 2024 | 85.89% |
| Sep 30, 2024 | 82.96% |
| Jun 30, 2024 | 82.88% |
| Mar 31, 2024 | 85.54% |
| Dec 31, 2023 | 77.27% |
| Sep 30, 2023 | 74.62% |
| Jun 30, 2023 | 77.35% |
| Mar 31, 2023 | 78.31% |
| Dec 31, 2022 | 76.79% |
| Sep 30, 2022 | 77.36% |
| Jun 30, 2022 | 77.72% |
| Mar 31, 2022 | 86.42% |
| Dec 31, 2021 | 78.84% |
| Sep 30, 2021 | 83.95% |